Group 1 - The core point of the article is that Yidu Technology (02158) experienced a significant stock price increase, rising over 14% in late trading, with a current price of HKD 6.57 and a trading volume of HKD 466 million [1] - Yidu Technology's subsidiary, Tianjin Happy Life Technology Co., Ltd., won a bid for the Phase III clinical research project of the human nerve growth factor (SMR001) eye drops from Shandong Yandu Biotechnology Co., Ltd., with a total project amount of approximately RMB 55.82 million [1] - On September 16, during the 2025 Tencent Digital Ecosystem Conference's medical session, Yidu Technology's Senior Solutions Expert Shi Chengfa delivered a speech on "AI Empowering the Full Process of Clinical Trials," discussing how AI can enhance the efficiency and quality of clinical trials, thereby promoting high-quality development in the industry [1]
医渡科技涨超14% AI有望赋能临床试验 附属中标SMR001滴眼液III期临床研究项目